Patent 9545434 was granted and assigned to Nps Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.
Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.